CoChat

Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression

Open access

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Background: Besides providing reassurance about cardiovascular (CV) safety of newer diabetes drugs, cardiovascular outcome trials (CVOTs) have also shown encouraging benefits on some CV endpoints. The contribution of the better glycemic control in the reduction of major cardiovascular events (MACE) remains an open question. The aim of this study is to evaluate the associations between the reduction of HbA1c and risk of MACE, MACE components, hospitalization for heart failure (HF) and all-cause death in CVOTs. Methods: An electronic search up to July 2021 was conducted to determine eligible trials. Systematic review identified eighteen CVOTs reporting prespecified CV outcomes. Pooled summary estimates and 95% confidence intervals (CI) were calculated according to the random effects model using the Paule-Mandel method; restricted maximum likelihood estimators were used to estimate model parameters in the metaregression. Results: The eighteen CVOTs evaluated 161,156 patients and included four trials with dipeptidyl-peptidase-4 inhibitors (DPP-4i), eight trials with glucagon-like peptide-1 receptor agonists (GLP-1RA) and six trials with sodium-glucose cotransporter-2 inhibitors (SGLT-2i). Random-effects model meta-analysis showed an association between treatment and risk of MACE (hazard ratio [HR] 0.90; 95% CI 0.86, 0.94, P < 0.001), with significant heterogeneity between studies (I 2 = 45.2%, Q statistic P = 0.040). In meta-regression, there was an association between the reduction in HbA1c at the end of the trial and the HR reduction for MACE (beta = − 0.298, P = 0.007), with significant heterogeneity (I 2 = 40%, Q statistic P = 0.04); this association was totally driven by the risk reduction of non-fatal stroke, which explained 100% of between-study variance (beta = − 0.531, R 2 = 100%), without heterogeneity (I 2 = 24%, Q statistic P = 0.206). There was no association between the reduction in HbA1c and the HR for heart failure or all-cause death. Conclusions: The reduction of HbA1c in eighteen CVOTs was significantly associated with reduction of non-fatal stroke, explaining all (R 2 = 100%) of the between-study variance. While the contribution of glucose lowering in some CV benefits of newer agents does not influence their indications for the patient with type 2 diabetes, it may hopefully facilitate their use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-021-01401-8

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Forest plot of risk (HR, hazard ratio) of MACE (major cardiovascular events) with the use of DPP-4i, GLP-1RA or SGLT-2i, as compared with placebo, in patients with type 2 diabetes participating in 18 CVOTs (cardiovascular outcome trials)
Fig. 1 Forest plot of risk (HR, hazard ratio) of MACE (major cardiovascular events) with the use of DPP-4i, GLP-1RA or SGLT-2i, as compared with placebo, in patients with type 2 diabetes participating in 18 CVOTs (cardiovascular outcome trials)CC BY · PubMed Central
Fig. 2 Meta-regression analysis between the differences (intervention minus placebo) in achieved HbA1c at the end of CVOTs and the corresponding hazard ratio (HR) for MACE (top) or non-fatal stroke (bottom) in patients with type 2 diabetes participating in 18 CVOTs
Fig. 2 Meta-regression analysis between the differences (intervention minus placebo) in achieved HbA1c at the end of CVOTs and the corresponding hazard ratio (HR) for MACE (top) or non-fatal stroke (bottom) in patients with type 2 diabetes participating in 18 CVOTsCC BY · PubMed Central
Fig. 3 Meta-regression analysis between the differences in achieved HbA1c at the end of cardiovascular outcome trials (CVOTs) and the corresponding hazard ratio (HR) for CV death in patients with type 2 diabetes participating in 18 CVOTs
Fig. 3 Meta-regression analysis between the differences in achieved HbA1c at the end of cardiovascular outcome trials (CVOTs) and the corresponding hazard ratio (HR) for CV death in patients with type 2 diabetes participating in 18 CVOTsCC BY · PubMed Central
Fig. 4 Meta-regression analysis between the differences in achieved HbA1c at the end of cardiovascular outcome trials (CVOTs) and the corresponding hazard ratio (HR) for non-fatal MI in patients with type 2 diabetes participating in 18 CVOTs
Fig. 4 Meta-regression analysis between the differences in achieved HbA1c at the end of cardiovascular outcome trials (CVOTs) and the corresponding hazard ratio (HR) for non-fatal MI in patients with type 2 diabetes participating in 18 CVOTsCC BY · PubMed Central
Fig. 5 Meta-regression analysis between the differences in achieved HbA1c at the end of cardiovascular outcome trials (CVOTs) and the corresponding hazard ratio (HR) for hospitalization for heart failure (HF) in patients with type 2 diabetes participating in 18 CVOTs
Fig. 5 Meta-regression analysis between the differences in achieved HbA1c at the end of cardiovascular outcome trials (CVOTs) and the corresponding hazard ratio (HR) for hospitalization for heart failure (HF) in patients with type 2 diabetes participating in 18 CVOTsCC BY · PubMed Central
Fig. 6 Meta-regression analysis between the differences in achieved HbA1c at the end of CVOTs and the corresponding hazard ratio (HR) for all-cause death in patients with type 2 diabetes participating in 18 CVOTs
Fig. 6 Meta-regression analysis between the differences in achieved HbA1c at the end of CVOTs and the corresponding hazard ratio (HR) for all-cause death in patients with type 2 diabetes participating in 18 CVOTsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 1

  1. Deeks JJ, Higgins JPT, Altman DG; the Cochrane Statistical Methods Group. Cochrane Handbook for Systematic Reviews of interventions. Version 6.1, 2020. Chapter 10: Analysing data and undertaking meta-analyses. Specify characteristics in advance. https://training.cochrane.org/handbook/current/chapter-10#section-10-11-4. Accessed 30 July 2021

Cited by

See all 80

Metadata

Authors
Maiorino, M. I., Longo, M., Scappaticcio, L., Bellastella, G., Chiodini, P., Esposito, K., & Giugliano, D.
Affiliations
University of Campania "Luigi Vanvitelli" (IT)
Corresponding author
Maiorino, Maria Ida
Venue
Cardiovascular Diabetology
Published
2021-10-18
Volume
20
Issue
1
Pages
210-210
ISSN
1475-2840 (ISSN-L)
OpenAlex
W3205244879
Cited by
72
References
49
Citations by year
2026: 5 · 2025: 12 · 2024: 24 · 2023: 14 · 2022: 15 · 2021: 2
FWCI
2.11
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
glycemic control, HbA1c reduction, major adverse cardiovascular events, cardiovascular outcome trials, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, type 2 diabetes, non-fatal stroke, heart failure hospitalization, all-cause mortality, study heterogeneity
MeSH terms
Glucagon-Like Peptide-1 Receptor, Sodium-Glucose Transporter 2 Inhibitors, Glycemic Control, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Blood Glucose, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Hospitalization, Humans, Male, Middle Aged, Risk Factors, Time Factors, Biomarkers, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment, Incretins, Dipeptidyl-Peptidase IV Inhibitors, Protective Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression. https://app.cochat.ai/papers/10.1186/s12933-021-01401-8
The paper
Maiorino, M. I., Longo, M., Scappaticcio, L., Bellastella, G., Chiodini, P., Esposito, K., & Giugliano, D. (2021). Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-021-01401-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.